The QualityStocks Daily Wednesday, March 31st, 2021

Today's Top 3 Investment Newsletters

InvestorBrandNetwork(HLTT) $3.19 +51.18%

MarketClub Analysis(WAFU) $12.50 +51.15%

QualityStocks(MVIS) $18.55 +50.69%

The QualityStocks Daily Stock List

Immutep Limited (NASDAQ: IMMP) (OTC: PRRUF) (ASX: IMM) (FRA: YP1B)

StockMarketWatch, MarketBeat, TradersPro, MarketClub Analysis, The Street, Real Pennies, Profitable Trader Authority, PennyStockProphet, Penny Pick Finders, OTCtipReporter, HotOTC, Buzz Stocks and BUYINS.NET reported earlier on Immutep Limited (IMMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Immutep Limited (NASDAQ: IMMP) (OTC: PRRUF) (ASX: IMM) (FRA: YP1B) is a biotechnology firm that is engaged in the research and development of pharmaceutical products. The firm develops immunotherapy treatments for autoimmune diseases and cancer.

Immutep Limited provides its services across the globe and was established on May 21, 1987. The firm has its headquarters in Sydney, Australia and was known as Prima BioMed Ltd before changing its name in November 2017.

Immutep Ltd operates in the biotechnology industry under the healthcare sector and aims to develop innovative treatment options for patients who have unmet needs that need to be addressed. The firm is party to partnerships with EOC Pharma, INSIGHT, CYTLIMIC Inc., Novartis and GlaxoSmithKline.

Immutep Ltd.’s product pipeline include a recombinant protein dubbed IMP321 which is currently being assessed as a combination therapy for non-small cell lung carcinoma and neck and head squamous cell carcinoma in a phase 2 clinical trial christened TACTI-002; as well as being evaluated in a combination therapy trial, currently in phase 1 for metastatis melanoma dubbed TACT-mel. This is in addition to undergoing a phase 2b clinical trial dubbed AIPAC as a chemoimmunotherapy combination for metastatic breast cancer and another phase 1 trial dubbed INSIGHT, which is evaluating the candidate’s efficacy against advanced solid tumors. The firm’s other products include IMP731, IMP701 and IMP761, which have all been linked to lymphocyte activation gene 3.

Immutep Ltd recently announced that it will be conducting a new phase 2b clinical trial which will be evaluating the efficacy of its IMP321 candidate. Successful results of the clinical trial in treating head and neck squamous cell carcinoma may in the future help address a previously unmet need for patients who suffer from this disease. This is in addition to boosting investment in the company.

Immutep Limited (IMMP), closed Wednesday's trading session at $3.07, up 6.5972%, on 552,930 volume with 2,279 trades. The average volume for the last 3 months is 2,611,448 and the stock's 52-week low/high is $0.629999995/$7.9499998.

Lipocine Inc. (NASDAQ: LPCN) (FRA: 2VT)

StockMarketWatch, MarketBeat, TraderPower, MarketClub Analysis, BUYINS.NET, TradersPro, StreetInsider, INO.com Market Report, Barchart, Daily Market Beat, Investing Futures, InvestorPlace, Jason Bond, QualityStocks, VectorVest, Schaeffer's, The Weekly Options Trader, Trades Of The Day and Marketbeat.com reported earlier on Lipocine Inc. (LPCN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lipocine Inc. (NASDAQ: LPCN) (FRA: 2VT) is a clinical stage biopharmaceutical company that uses its oral drug delivery technology to develop pharmaceutical products for the treatment of endocrine and metabolic disorders.

Lipocine Inc. serves consumers in the United States and was founded in 2011. The company has its headquarters in Salt Lake City, Utah and its main development programs are based off of oral delivery solutions for poorly bioavailable drugs.

Lipocine Inc. has a pipeline of candidates that have been designed to decrease side effects, bypass first-pass metabolism in specific cases, facilitate lower dosing requirements, give rise to pharmacokinetic characteristics and also get rid of gastrointestinal interactions that limit bioavailability.

Lipocine Inc.’s lead product candidate is an oral testosterone replacement therapy known as TLANDO. Other candidates include a hydroxyprogesterone caproate product that concluded a phase 2 dose finding clinical trial for the prevention of recurrent preterm birth, christened LPCN 1107; an oral prodrug that recently ended its phase 1 clinical trial for NASH treatment called LPCN 1148; a testosterone oral prodrug that recently concluded its phase 2 clinical trials in hypogonadal men that’s used once daily called (LPCN 1111) TLANDO XR and an oral bioidentical testosterone prodrug that’s currently undergoing a phase 2 clinical trial for the treatment of NASH (non-alcoholic steatohepatitis) dubbed LPCN 1144.

As of December 2020, the FDA had granted tentative approval for Lipocine Inc.’s TLANDO candidate as an oral testosterone replacement therapy for adults. The FDA noted that the candidate has met all required efficacy, safety and quality standards necessary for approval and may soon be granted final approval once its exclusivity period, that had been granted to Clarus Therapeutics Inc., expires. This move will allow it to be commercialized, which will not only benefit the market’s consumers but also the company’s revenue stream as well as its investment portfolio.

Lipocine Inc. (LPCN), closed Wednesday's trading session at $1.51, up 4.8611%, on 886,266 volume with 2,753 trades. The average volume for the last 3 months is 5,282,813 and the stock's 52-week low/high is $0.405000001/$2.42000007.

LM Funding America Inc. (NASDAQ: LMFA) (FRA: 1YJA)

StockMarketWatch, Marketbeat.com, BUYINS.NET, TradersPro, TraderPower, MarketClub Analysis, MarketBeat, PennyStockProphet, Buzz Stocks, HotOTC, OTCtipReporter, Penny Stock, WealthMakers, Profitable Trader Authority, QualityStocks, StockOnion and Penny Pick Finders reported earlier on LM Funding America Inc. (LMFA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

LM Funding America Inc. (NASDAQ: LMFA) (FRA: 1YJA) is a specialty finance firm that operates through its LM Funding LLC subsidiary. The firm offers funding to non-profit community associations located in Florida as well as in the states of Illinois, Colorado and Washington.

LM Funding America Inc. serves consumers throughout the U.S. and was founded on January 14, 2008. The firm has its headquarters in Tampa, Florida and was established by Carollinn Gould.

The company provides nonprofit community associations a range of financial products that can be customized to meet each association’s financial needs. The firm’s products include the new neighbor guaranty and original product. The original product is comprised of offering funding to associations by buying their purchasing rights under delinquent accounts that have been picked by the associations arising from association assessments that have not been paid. On the other hand, LM Funding America Inc. buys delinquent accounts on different terms that have been tailored to suit an association’s needs, under its new neighbor guaranty program. The firm also offers medical insurance products for international travelers.

LM Funding America Inc. recently launched its IPO through its blank check company LMF Acquisition Opportunities. The firm plans to target businesses in the financial services industry and related sectors, with enterprise values between $250-$500 million. This move will not only boost the parent company’s growth but also allow significant expansion in the sector, which will most likely draw in investors.

LM Funding America Inc. (LMFA), closed Wednesday's trading session at $1.29, up 0.78125%, on 747,665 volume with 1,570 trades. The average volume for the last 3 months is 14,212,420 and the stock's 52-week low/high is $0.300000011/$4.88999986.

Neovasc Inc. (NASDAQ: NVCN) (TSE: NVCN) (FRA: G5Z3)

StockMarketWatch, StreetInsider, MarketBeat, BUYINS.NET, TraderPower, Promotion Stock Secrets, Hit and Run Candle Sticks, Rick Saddler, Zacks, Schaeffer's, Barchart, Marketbeat.com, Stock Market Watch, Jason Bond, Investing Futures, Streetwise Reports, Daily Trade Alert, Wealth Insider Alert and MarketClub Analysis reported previously on Neovasc Inc. (NVCN), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Neovasc Inc. (NASDAQ: NVCN) (TSE: NVCN) (FRA: G5Z3) is a specialty medical device firm that is engaged in the manufacture, development and marketing products for the cardiovascular marketplace which is growing rapidly. Neovasc Inc. serves consumers in the United States, Europe, Canada as well as internationally and was established on November 2, 2000. The firm has its headquarters in Richmond, Canada and was known as Medical Ventures Corp., before changing its name in 2008.

Neovasc Inc.’s segment is the development, manufacture and marketing of medical devices. The firm focuses on Neovasc Reducer and Neovasc Tiara products. The reducer has been developed for the treatment of refractory angina while the tiara has been designed for mitral valve disease treatment.

The reducer is a bare metal stainless steel balloon-expandable hourglass shaped device which is usually implanted in a patient’s coronary sinus, and it creates a restriction in venous outflow from the muscular layer of an individual’s heart. The tiara is currently in early clinical stage/preclinical development to offer a minimally invasive trans catheter device for patients who experience mitral regurgitation as a results of mitral valve heart disease. The firm also develops a biological tissue product that is manufactured from pericardium, known as Peripatch.

The heart valve repair and replacement market is set to grow significantly this year and given that Neovasc Inc. is one of the companies that is involved in the market, it’s safe to assume that the company will experience growth that will not only afford it with more opportunities for expansion but also boost investments.

Neovasc Inc. (NVCN), closed Wednesday's trading session at $1.08, up 2.8571%, on 800,395 volume with 2,379 trades. The average volume for the last 3 months is 6,195,578 and the stock's 52-week low/high is $0.680000007/$3.88000011.

Acquired Sales Corp. (AQSP)

QualityStocks, SmallCapVoice and Money Morning reported beforehand on Acquired Sales Corp. (AQSP), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Acquired Sales Corp. is a consolidator of companies making branded cannabinoid-infused products. These products include beverages, muscle/joint rubs, oils, crystals, tinctures, bath bombs, and isolate. Additionally, products include relief balms, elixirs, body washes, med sticks, lotions, vape pens and cartridges, shatter, and gummies. On February 24, 2020, the Company acquired 100 percent of fast growing and profitable Warrender Enterprise, Inc. d/b/a Lifted Made (formerly d/b/a Liquids), of Zion, Illinois. Acquired Sales has its corporate headquarters in Lake Forest, Illinois.

The Company believes in the value of cannabinoids (CBD, CBG, CBN, etc.). Furthermore, it owns 4.99 percent of CBD-infused beverage and products maker Ablis Holding Company, and of craft distillers Bendistillery, Inc. d/b/a Crater Lake Spirits and Bend Spirits, Inc., Bend, Oregon, that it purchased in 2019 for $1,896,200 in cash.

The Company’s House Brands include Lifted Made. This is the distinguished house of creative cannabis products targeting astute consumers who demand the highest quality products, speedy delivery systems, and lasting effects.

Moreover, House Brands include Levé-Pâte De Fruit. Levé is a cannabis-infused confectionary brand, centered around the highest quality vegan ingredients imported from France. Another House Brand is Urb-Finest Flower. Urb is an exclusive cannabis hemp flower brand. Urb is focused around supporting U.S. farmers, using rare hemp genetics (strains) paired with one-of-a-kind packaging.

Recently, Lifted Made announced its launch of the world’s first hemp-derived delta-8-THC nano-particle drops under Lifted Made’s flagship brand Urb Finest Flowers. Urb’s delta-8-THC nano drops are a flavored, water soluble tincture and beverage additive, and are federally legal. The nano drops sell in a one ounce bottle and contain 333 mg. of delta-8-THC and less than 0.3% delta-9-THC. At present, the product is available for purchase in three flavors: Go Grape, Let’s Mango, and Orange Dream.

Lifted Made also previously announced its launch of flavored nano CBD water enhancer packets under Lifted Made’s flagship brand Urb Finest Flowers. Urb’s nano CBD water enhancer packets are water soluble and are available in four flavors. These are mango, blue razz, watermelon, and lemon. Each packet contains roughly 10 mg. of CBD, and less than 0.3% delta-9-THC.

Acquired Sales Corp. (AQSP), closed Wednesday's trading session at $7.50, up 23.9669%, on 909 volume with 11 trades. The average volume for the last 3 months is 2,665 and the stock's 52-week low/high is $1.25/$11.00.

Vireo Health International, Inc. (VREOF)

QualityStocks, TradersPro, The Street and InvestorPlace reported earlier on Vireo Health International, Inc. (VREOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQX-listed, Vireo Health International, Inc. is a leading science-focused, multi-state cannabis enterprise. Its corporate mission is to build the cannabis company of the future through bringing the best of medicine, engineering, and science to the cannabis industry. The Company has operations strategically located in early-stage, limited-license medical markets. Vireo Health International is based in Minneapolis, Minnesota. Vireo Health of New York is a subsidiary of Vireo Health International.

Vireo Health International collaborates with research organizations to better understand medical cannabis, its applications, and its safety. These partnerships help to reinforce and improve the scientific foundation of the beneficial effects of cannabis and its ability to treat an assortment of medical conditions.

Vireo Health’s physician-led team of employees provides best-in-class cannabis products and customer experiences. The Company manufactures pharmaceutical-grade cannabis products in environmentally-friendly greenhouses. It distributes its products by way of its increasing network of Green Goods™ retail dispensaries and hundreds of third-party locations.

The Company’s present core medical markets of New York, Minnesota, Pennsylvania, Arizona, New Mexico, and Maryland all have the potential to enact adult-use legalization in the next 24 months. In addition, two additional markets in Puerto Rico and Massachusetts have potential for commercialization.

Vireo’s teams' emphasis is on driving scientific innovation within the industry and securing meaningful intellectual property (IP). Vireo’s belief is that it is well positioned to become an international market leader in the cannabis industry. Today, eight of the Company’s 10 markets are operational; 13 of its 32 total retail dispensary licenses are open for business.

Vireo’s products contain highly-purified, double-distilled, precisely formulated medical marijuana extracts with strain specific terpenes to maximize the entourage effect. Its extracts and oral solutions include Vireo Red (19.1), Vireo Yellow (6.1), Vireo Green (1.1), Vireo Blue (6.1), and Vireo Indigo (19.1). These numbers represent the THC (tetrahydrocannabinol) to CBD (cannabidiol) ratio.

Vireo Health International has launched LiteBud. This is a patent-pending line of consistently formulated, lower THC cannabis products designed to meet the needs of cannabis consumers looking for a more consistent, controlled, as well as mild experience.

Recently, Vireo Health International announced that it completed the sale of its equity in Pennsylvania Medical Solutions, LLC (PAMS) to Jushi, Inc, a subsidiary of Jushi Holdings, Inc. (CSE: JUSH) (OTCQB: JUSHF), for a total consideration of $37 million. Pennsylvania Medical Solutions holds a permit for the cultivation and processing of medical cannabis in the State of Pennsylvania. Vireo Management expects to use a portion of the transaction proceeds for capital expenditures (capex), which will increase scale in its core markets of New York, Minnesota, Maryland, Arizona, and New Mexico.

Vireo Health International, Inc. (VREOF), closed Wednesday's trading session at $2.3899, up 30.5956%, on 861,543 volume with 1,495 trades. The average volume for the last 3 months is 506,034 and the stock's 52-week low/high is $0.294999986/$3.83999991.

Western Uranium & Vanadium Corp. (WSTRF)

QualityStocks and TradersPro reported  previously on Western Uranium & Vanadium Corp. (WSTRF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Western Uranium & Vanadium Corp. is a uranium and vanadium conventional mining company. It focuses on low cost near-term production of uranium and vanadium in the western United States, and also the development and application of ablation mining technology. Ablation Mining Technology (AMT) is a proprietary process that improves efficiency and lessens costs for sandstone hosted deposits. Western Uranium & Vanadium has offices in Toronto, Ontario and Nucla, Colorado. The Company lists on the OTCQX.

Western Uranium & Vanadium is among the largest U.S. Uranium and Vanadium in-situ resource holders. It has a total uranium resource of 70,000,000 lbs. +/- and a total vanadium resource of 35,000,000 lbs. +/- grading between 1.4-2.2 percent. Its near-term production strategy includes focusing on previously producing mines for low capex (capital expenditures), existing infrastructure, and permitting.

The Company’s strategy also includes defining and developing a high-grade vanadium resource at the Sunday Mine Complex (SMC). Furthermore, its strategy is to deliver SMC ore samples to numerous potential customers and joint venture (JV) partners, and baseload SMC production with a vanadium ore concentrate agreement.

Moreover, Western Uranium & Vanadium’s strategy is to pursue vanadium development at the Sage Mine Project. It will also work to pursue uranium contracts and development at prices above current price levels.

The Sunday Mine Complex was reopened in 2019 with development and mining of ore conducted and stockpiled in the mines. During the 3rd and 4th Quarters of 2019, the project emphasis was shifted to surface infrastructure projects. In February 2020, the last of these projects, the construction of the ore storage pads were completed. In March 2020, the completion reports were submitted to, reviewed, and accepted by the Colorado Division of Reclamation, Mining and Safety (DRMS). The surface projects are now complete.

Regarding the Division of Reclamation, Mining and Safety Permit Hearing, the hearing on the status of the Sunday Mine Complex permits is now scheduled for June 24, 2020. A further delay is possible depending on the safe distancing rules in place in late June.

Western Uranium & Vanadium Corp. (WSTRF), closed Wednesday's trading session at $1.55, up 22.0472%, on 485,966 volume with 1,097 trades. The average volume for the last 3 months is 131,373 and the stock's 52-week low/high is $0.254099994/$1.59109997.

MicroVision, Inc. (MVIS)

InvestorPlace, SmarTrend Newsletters, Schaeffer's, TradersPro, TraderPower, MarketBeat, StockOodles, QualityStocks, StockEgg, Greenbackers, OTCPicks, HotOTC, StreetInsider, The Street, CoolPennyStocks, Hit and Run Candle Sticks, Wall Street Resources, BullRally, PennyStocks24, PennyTrader Publisher, Penny Invest, StockMarketWatch, Real Pennies, PennyInvest, Bull Warrior Stocks, BUYINS.NET, MadPennyStocks, AllPennyStocks, MicrocapVoice, Stock Rich, WiseAlerts, Stock Analyzer, PennyStockVille, StockRich, Barchart, Wealth Daily, Trades Of The Day, TopPennyStockMovers, Buzz Stocks, Timothy Sykes, DrStockPick, FeedBlitz, FNNO Newsletters, Stockpalooza, PennyOmega, InvestmentHouse, Stock Fortune Teller, Jason Bond, SmallCapVoice, Marketbeat.com, SmallCap Network, Momentum Traders, Promotion Stock Secrets, Profit Confidential, Penny Stock Rumble and Investing Futures reported previously on MicroVision, Inc. (MVIS), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

MicroVision, Inc. is a leader in unique ultra-miniature laser display and sensing technology. It is the creator of PicoP® scanning technology. This is an ultra-miniature sensing and projection solution founded on the laser beam scanning (LBS) methodology pioneered by the Company. MicroVision’s platform approach for this advanced sensing and display solution means that it can be adapted to a broad variety of applications and form factors. Established in 1993, MicroVision has its corporate office in Redmond, Washington. The Company lists on the NasdaqGS.

MicroVision has a considerable portfolio of patents relating to laser beam scanning projection and sensing. Its patented PicoP® Scanning Technology employs an ultra-miniature MEMS mirror to scan a modulated laser beam using state-of-the-art control systems. The core technology is the platform for application-specific PicoP® Scanning Engines for use in 3D sensing, interactive displays, as well as projected displays.

PicoP® scanning technology provides enhanced image quality, with an HD picture that is always-in-focus. This is from an engine the fraction of the size of a business card and only several mm thick. The Company’s scanning technology enables a vital piece of the augmented reality puzzle—the display. Its solution enables large field-of-view, highly transparent, HD images with extremely low latency and persistence.

MicroVision’s technology enables it to create high resolution miniature projection displays and LiDAR sensors. The core technology is the basis for manifold products in three primary application segments: Display Applications, Sensing Applications, and Display + Sensing Applications (Interactive Projection Display Engine).

Recently, MicroVision announced it elected Dr. Mark B. Spitzer to its Board of Directors. Dr. Spitzer is an experienced technology innovator. He has expertise in eyewear- and head-mounted systems, micro-displays, imaging optics for AR and VR, as well as photovoltaics.

Dr. Spitzer is a Fellow of the American Physical Society and a Senior Member of the IEEE. In 2014, he received the Special Recognition Award from the Society for Information Display in 2014 for contributions to the development of active-matrix liquid-crystal micro-displays, micro-display viewing optics, and wearable computer technology.

MicroVision, Inc. (MVIS), closed Wednesday's trading session at $18.55, up 50.6905%, on 56,686,153 volume with 271,510 trades. The average volume for the last 3 months is 14,464,825 and the stock's 52-week low/high is $0.170000001/$24.1800003.

Wize Pharma, Inc. (WIZP)

We reported previously on Wize Pharma, Inc. (WIZP), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

Wize Pharma, Inc. focuses on the treatment of ophthalmic disorders. This includes dry eye syndrome (DES). The OTCQB-listed Company previously went by the name Star Night Technologies Ltd. It changed its corporate name to Wize Pharma, Inc. in July of 2015. A clinical-stage biopharmaceutical enterprise, the Company is headquartered in Hod Hasharon, Israel.

Wize Pharma has in-licensed certain rights to purchase, market, sell, and distribute a formula named LO2A. This is a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis (CCH) and Sjögren's Syndrome. Currently, LO2A is registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH, and in the Netherlands for the treatment of DES and Sjögren's Syndrome.

Wize Pharma is now conducting a Phase II trial of LO2A for patients with CCH and a Phase IV study for LO2A for DES in patients with Sjögren's. The Company announced in March of last year that it enrolled the initial patient in its Phase IV clinical trial in Israel for LO2A in the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome. This randomized, double-masked study is evaluating LO2A versus Alcon's Systane® Ultra UD, an over-the-counter (OTC) lubricant eye drop product used to relieve dry and irritated eyes.

The design of the study (in addition to meeting marketing approval requirements in Israel) is to support Wize Pharma’s clinical approval pathway for LO2A for the treatment of DES in patients with Sjögren's in other markets including the U.S., China, and Ukraine. LO2A is already approved in Israel for the treatment of DES.

This past November, Wize Pharma announced top line results from its Phase II clinical trial in Israel of LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with moderate to severe conjunctivochalasis (CCh). Wize Pharma's Chairman, Noam Danenberg, stated, "We are very pleased with these top line results and we look forward to analyzing the full results. We believe the full results from this study, will support our clinical development path and provide firm basis for presentation and discussions with the FDA for the approval pathway of LO2A in the U.S. and additional countries."

Previously, Wize Pharma announced that it signed an agreement with Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) to form a joint venture (JV) company for researching, developing and administering cannabinoid formulations to treat ophthalmic conditions. Cannabics Pharmaceuticals is a global leader in personalized cannabinoid medicine centered on cancer and its side effects.

Wize Pharma, Inc. (WIZP), closed Wednesday's trading session at $1.015, up 14.0449%, on 170,278 volume with 146 trades. The average volume for the last 3 months is 157,976 and the stock's 52-week low/high is $0.072999998/$1.45000004.

Voip-Pal.com, Inc. (VPLM)  

QualityStocks, Equities.com, Mega Stock Pick, Pumps and Dumps, HotOTC, Stock Rich, Pick Alerts, BullRally, Buzz Stocks, Clutch Investments, CoolPennyStocks, equities Canada, Google Alerts, Monster OTC, Penny Stock Fever, StockEgg, MajorPennyStocks, Breaking Bulls, Bullish Stock Picks, Wallstreetbuzz, Bullseyestox.com, VC Stock Marketing, UndiscoveredEquities, TryBestPennyStocks.biz, TooNiceStocks, TheSUBWAY, FeedBlitz, Stockoutlaws, Penny Invest, HotStockProfits, SmallCapAllStars, Mega Stock Picks, Stock Twiter, NYC Marketing Inc, Best Stock Picks, Stock Traders Chat, WallstreetsHotteststocks, Premiumstockpicks, Promotion Stock Secrets, Stock Fortune Teller, SmallCapVoice and StockHotTips reported previously on Voip-Pal.com, Inc. (VPLM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Voip-Pal.com, Inc. owns a portfolio of patents relating to Voice-over-Internet Protocol (VoIP) technology. The OTCQB-listed Company is now looking to monetize its fundamental patents by way of a sale or licensure of its technology. In December 1997, Voip-Pal.com incorporated in the State of Nevada. In 2013, it acquired Digifonica International (DIL) Limited to fund, co-develop, and complete Digifonica's patent collection. Voip-Pal.com has its corporate office in Bellevue, Washington.

Voip-Pal’s Intellectual Property (IP) value comes from manifold issued US Patent and Trademark Office (USPTO) patents. This includes five parent patents, one of which is foundational and the others that build upon the former. The five core patents are: Routing, Billing & Rating (RBR);  Lawful Intercept; Enhanced E-911; Mobile Gateway; and Uninterrupted Transmission.   Voip-Pal.com’s patented technology provides Universal numbering ubiquity; network value as defined by Metcalfe; the imperative of interconnect, termination, and recompense for delivery of calls by other networks; and regulatory compliance in regulated markets. Additionally, the Company’s patented technology provides interconnection of VoIP networks to mobile and fixed networks; and maintenance of uninterrupted VoIP calls across fixed, mobile, and Wi-Fi networks. Voip-Pal believes that its Lawful Intercept patents could prove to be a vital tool for law enforcement in its efforts to combat crime and stop terror attacks. The technology provides the means for judicially authorized covert intercept of any kind of communications sent through VoIP. This includes voice calls, media, as well as messaging. The Company’s U.S. patent portfolio has grown from five core patents to 20 issued patents or allowed applications, and a number of pending patent applications in different stages of examination at the USPTO.

Voip-Pal.com, Inc. (VPLM), closed Wednesday's trading session at $0.0222, up 21.978%, on 9,008,772 volume with 106 trades. The average volume for the last 3 months is 3,152,888 and the stock's 52-week low/high is $0.006/$0.047400001.

Khiron Life Sciences Corp. (TSX.V: KHRN) (OTCQX: KHRNF)

QualityStocks and Trading For Keeps reported previously on Khiron Life Sciences Corp. (KHRNF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Khiron Life Sciences (TSX.V: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) (“Khiron” or the “Company”) is a vertically integrated cannabis leader with core operations in Latin America and Europe. The company trusts in the vast benefits of medical cannabis and is committed to improving the life quality of patients and consumers through the applied use of cannabis and technology.

Khiron is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products, having achieved first sales in March 2020 and medical cannabis insurance coverage in December 2020. Additionally, the Company has commenced medical cannabis sales in the United Kingdom, Peru, and Germany, with Mexico and Brazil also anticipated this year. Khiron operates six wholly owned health centres in Colombia, where it completed more than 100,000 patient transactions in 2020. The Company is currently expanding patient access in Latin America through satellite clinics, with plans to accelerate growth in Europe by leveraging assets developed in Colombia, including clinical IP, genetics, and data.

Khiron has successfully exported its registered cannabis strains, in the form of live clones, from Colombia to Europe. This significant milestone represents the first shipment of medical cannabis live plant material to Europe from Colombia and is expected to accelerate access to European markets.

Tejinder Virk (Khiron’s European Managing Director and President) explains the process of certifying the company’s cannabis strains for export to Europe by way of clones:

“A clone is a cannabis plant that is a genetic copy of a mother plant. These clones were cut from our THC and CBD bearing mother plants in Colombia, which are used to make medicines for thousands of our patients in Latin America (over 10,000 prescriptions to date and growing quickly!). Europe has a population of nearly 748 million people and there is enormous patient need for cannabis-based medicines. However, doctors in Europe need solid clinical evidence to confidently prescribe medical cannabis for ailments such as pain, sleep or anxiety. By replicating our Colombian magistrals as EU GMP certified medicines, we aim to provide European doctors with practical clinical evidence from Colombia. This will also help ensure European patients get safe and efficacious treatment. The achievement demonstrates our global regulatory leadership and ability to export our intellectual property to other markets.”

As the management team executes its growth strategy throughout the United Kingdom and Germany by introducing branded extracts and dried flower products, Khiron continues to validate its patient-centric strategy with over 13,000 prescriptions written to date amid plans to reach 1 million patients and consumers by 2024.

Most recently, the first shipment of Khiron-branded EU-GMP certified cannabinoid-based medicine was successfully completed, providing immediate access to the German market through Khiron’s distribution partner, Nimbus Health GmbH, a leading EU-GMP/GDP certified medical cannabis distributor in Germany, with a network of over 300 pharmacies. Khiron teams continue to educate physicians with plans to leverage clinical evidence from both the UK and Colombia. This major milestone represents a new revenue stream for Khiron and positions Khiron’s European team to execute on its German medical strategy.

As a revolutionary, patient-focused, global leader of medical cannabis from Latin America, Khiron offers products that are manufactured in GMP-GEP compliant facilities in Colombia and are standardized and stabilized according to the U.S. Pharmacopeia analytics standard (USP42). Khiron believes, with its extremely skilled management team, that the company will be a frontrunner in the global medical cannabis market, which is expected to reach $44 billion by 2024 (https://cnw.fm/mX1Yn) and $84 billion by 2028 (https://cnw.fm/k9gFl).

Khiron Life Sciences Corp. (KHRNF), closed Wednesday's trading session at $0.4452, off by 0.06734%, on 217,977 volume with 99 trades. The average volume for the last 3 months is 838,914 and the stock's 52-week low/high is $0.25/$0.646300017.

Graybug Vision Inc. (NASDAQ: GRAY)

StreetInsider and MarketBeat reported beforehand on Graybug Vision Inc. (GRAY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Graybug Vision Inc. (NASDAQ:GRAY) traded at a new 52-week low today of $5.34. Approximately 488,000 shares have changed hands today, as compared to an average 30-day volume of 640,000 shares.

Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company's products under pipeline are GB-102, for the treatment of wet age-related macular degeneration, or wet AMD, and diabetic macular edema, or DME; GB-103; and GB-401.

Graybug Vision Inc. share prices have moved between a 52-week high of $37.88 and the current low of $5.34 and are currently at $5.67 per share.

Graybug Vision Inc. has overhead space with shares priced $5.67, or 1.8% below the average consensus analyst price target of $5.78.

Graybug Vision Inc. (GRAY), closed Wednesday's trading session at $5.55, off by 0.179856%, on 737,094 volume with 5,554 trades. The average volume for the last 3 months is 376,606 and the stock's 52-week low/high is $5.71999979/$37.8799018.

The QualityStocks Company Corner

Hero Technologies Inc. (OTC: HENC)

The QualityStocks Daily Newsletter would like to spotlight Hero Technologies Inc. (OTC: HENC) .

Hero Technologies Inc. (OTC: HENC) was featured today in a publication from CBDWire, examining ways in which the company is 'One to Watch,' as Hero Technologies expands into the Colorado and Massachusetts cannabis markets via two wholly owned subsidiaries. Also today, the company announced that its subsidiary, BlackBox Systems and Technologies LLC, has produced detailed cost, revenue, and profit projections for cannabis production on the 120-acre property in Jackson, Michigan the company plans to purchase.

Hero Technologies Inc. (OTC: HENC) is a cannabis company with a vertically integrated business model and plan that includes cannabis genetic engineering, farmland for medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, retail operations and dispensaries that make the organization a multi-state operator (MSO).

The company was founded in 2004 and is headquartered in Dover, Delaware.

Portfolio

The company holds the majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation firm focused on providing optimal conditions to enhance photosynthesis and cultivation. Hero Technologies is planning expansion in cultivation and dispensary operations in Colorado through wholly owned subsidiary Mile High Green LLC, while expansion in Massachusetts is planned through another wholly owned subsidiary, MassCannabis LLC.

Hero Technologies also owns and operates HighlyRelaxing.com under Highly Relaxing LLC and recently acquired the assets of V Brokers LLC, now operating as Veteran Hemp Co. at VeteranHempCo.com.

BlackBox Systems and Technologies LLC

BlackBox Systems and Technologies LLC markets a proprietary cannabis aeroponic cultivation system designed for the large-scale production of top-shelf cannabis products. BlackBox offers the optimal conditions to enhance photosynthesis and promote the cultivation of large flowering plants. The system’s dry room, process room and secure storage were designed for precise control through each phase of the cannabis lifecycle. Weekly harvests are achieved using 13 separate BlackBox systems in independent modules.

The system provides a series of key benefits, including:

  • High-pressure nutrient delivery, with no nutrient or PH deficiencies
  • Sterile, 100% nutrient solution
  • Drain to Waste (no reuse of wastewater)
  • Low water usage (1 gallon per plant per day)
  • Constant PH and EC in reservoirs
  • Modular design (1 to 100 pods in any configuration)
  • Innovative proprietary engineering
  • Minimal cleanup
  • Media-less growing, suspended in the air, with no media waste
  • No pesticides

Highly Relaxing LLC

Highly Relaxing LLC is an emerging Henderson, Nevada-based operation dedicated to providing customers with honestly labeled, high-quality hemp-derived CBD products. Its current offerings include a topical CBD cream that provides localized relief from potential discomfort.

Veteran Hemp Co.

Veteran Hemp Co.’s mission is to provide a quality, consistent and delicious product for Americans looking to enjoy the hemp smoking experience. Its product is brought in by only the finest farming operations delivering the best genetics. Veteran Hemp Co. has its own custom harvest plans, drying facilities and all of the logistics that fall between. Veteran Hemp Co. prides itself on being a veteran-approved company.

Market Outlook

The global legal cannabis market is anticipated to reach $84 billion by 2028, expanding at a CAGR of 14.3% from 2021 to 2028. The driving factor for this forecast expansion is the increasingly widespread legalization of cannabis for medical and recreational use. Recreational use accounted for 60.3% of industry revenue in 2020.

North America provided the largest revenue share in the cannabis market, accounting for 91.1% of the global market in 2020. Due to the early legalization of medical and recreational cannabis in the region, the customer pool has increased exponentially (https://nnw.fm/snpHh).

The global CBD market was valued at $2.8 billion in 2020 and is expected to grow at a CAGR of 21.2% and reach $13.4 billion by 2028. North America is considered the most progressive region for cannabis and its derived products, with the highest number of CBD companies being based on the continent. The B2B (business to business) segment dominates the CBD industry, accounting for the largest revenue share at 59.6% in 2020 (https://nnw.fm/cGxXQ).

With its vertically integrated business model and development into a multi-state operator across multiple sectors of the cannabis industry, Hero Technologies is uniquely positioned to capitalize on the fast-growing market and the growing number of opportunities emerging as a result of legalization and increased popularity among consumers.

Management Team

Gina Serkasevich, CPA, CMA, is the Chief Executive Officer, Treasurer and Secretary of the Hero Technologies. She previously worked for Holloman Corporation as its Director of Finance beginning in June 2012 and was appointed Chief Financial Officer of Holloman Energy Corporation in August 2014. She has more than 30 years of domestic and international corporate accounting and finance experience. She served as U.S. Controller for EFLO Energy Inc., a company focused on the acquisition, exploration and development of oil and gas assets in North America. Prior to 2012, Ms. Serkasevich worked in the oil and gas tanker transportation industry as a Regional Financial Manager for AET Inc. Limited (2011-2012), as a Financial Consultant for OSG Ship Management Inc. (2009-2011) and as a Financial Controller/CFO for Stena Bulk LLC (1998-2008). During her 11-year tenure at Stena Bulk LLC, she established the financial, accounting and reporting requirements for its new joint ventures and tanker pools with Sonanagol USA and held the Company Secretary position on both of those companies’ boards of directors.

Dan McCarthy is the company’s Corporate Development Manager. He has spent more than 12 years in the institutional investment community, holding various investment banking and private equity executive roles. Thus far, he has been a part of over $1 billion in transactional value ranging from debt and equity to acquisitions and diversities throughout his career. Mr. McCarthy’s most recent role was Managing Director at Petro Capital, a Dallas-based private equity and investment bank. He began his career working for a private international consulting firm based in Washington, D.C., helping corporations and funds expand into non-G7 countries utilizing World Bank financing. He is also a graduate of the University of Kansas School of Business and completed the Mergers and Acquisitions program at the New York Institute of Finance.

James Rowland is Hero Technologies’ Marketing Advisor and an expert in marketing and e-commerce. He has held many high-level marketing and business-related roles. He is the Founder and current CEO of PerfectCheckout.com and the current Business Development Specialist at Fulfillment.com. Mr. Rowland has held multiple high-level positions throughout his career, which have provided him with the experience needed to bring success-backed marketing leadership skills to his current role with the company.

Hero Technologies Inc. (HENC), closed Wednesday's trading session at $0.15, up 102.977%, on 43,163,448 volume with 7,088 trades. The average volume for the last 3 months is 1,106,049 and the stock's 52-week low/high is $0.020999999/$0.317400008.

Recent News

Mohawk Group Holdings Inc. (NASDAQ: MWK)

The QualityStocks Daily Newsletter would like to spotlight Mohawk Group Holdings Inc. (MWK).

Mohawk Group Holdings (NASDAQ: MWK) finished the financial year ended December 31, 2020, on a high note reporting $185.7 million in revenue, an increase of 62.3% or $71.3 million compared to a similar period in 2019, backed by an impressive fourth-quarter performance, which included improved profitability, strong growth in sales and revenue, and boosted guidance, as highlighted in a recent Motley Fool article titled “Mohawk Just Wrapped Up a Perfect 2020” (https://ibn.fm/fl95B).

Mohawk Group Holdings Inc. (MWK) is a leading tech-enabled consumer products platform that uses machine learning, natural language processing and data analytics to design, develop, market, and sell products. The company’s proprietary AIMEE(R) platform leverages data and AI to automate the design, development and launch of best-selling consumer products.

Mohawk owns and operates 12 brands and sells consumer products in multiple categories ranging from kitchenware and home appliances to environmental appliances, beauty products and even consumer electronics.

Founded in 2014, Mohawk has offices in the United States, Canada, China and the Philippines. The company is always working to capitalize on the strength of the different cities and time zones in which it operates to ensure continued excellence around the world and achieve its goal of becoming the most consumer-centric product company.

AIMEE(R) Platform

AIMEE(R) (AI Mohawk E-commerce Engine) is Mohawk’s proprietary platform that leverages data and AI to:

  • Identify new market opportunities;
  • Launch new products;
  • Automate marketing variables; and
  • Analyze and optimize company-owned and operated consumer product brands.

The platform’s core functionalities include:

  • Research: Automated research using live market data that tracks exposure and product trends, allowing for the swift discovery of new market and product opportunities;
  • Financials: Places data insights in one place, enabling execution across multiple channels to track new product planning, financial projections, inventory levels, media buying and more;
  • Trading: The result of an algorithmic solution that has been optimized for live decisions to scale sales and built to implement automated marketing strategies with learning through experimentation; and
  • Logistics: Manages logistics to enable faster delivery of products to consumers.

Mohawk’s Business Model

Mohawk’s unique business model is designed to drastically shorten go-to-market time, decreasing the typical 18- to 24-month process to just 6- to 8-months. Using AIMEE(R), Mohawk leverages real-time data-driven opportunities and trend tracking to replace the idea focus group research and development of the standard model.

Marketing time is also reduced between the two models using the AIMEE(R) Trading Engine for data-driven automated marketing and product lifetime management. Through the AIMEE(R) trading engine, the traditional 3-month marketing for a standard go-to-market model is cut to a fraction of the time.

The AIMEE(R) Fulfillment Engine allows for dynamic inventory allocation, fulfillment selection, cost optimization, a third-party logistics network and a 2-day shipping period across almost all of the United States. The standard business model doesn’t support direct distribution or an FBA (fulfilled by Amazon) structure.

Opportunities for Growth and Profitability

Mohawk’s plan to drive growth and profitability in the market includes:

  1. The continued optimization of product economics by lowering manufacturing and logistical costs through an increase in purchasing power
  2. The pursuit of higher-value products with larger target markets
  3. Opportunistically adding new products and categories through acquisitions
  4. Expansion into the international and new domestic e-commerce marketplaces
  5. Monetization of its proprietary AIMEE(R) platform by providing access to third-party brands

Mohawk’s long-term goal is to increase its profit margin from 14% in 2020 to 18-20%, using higher average selling prices and lower fulfillment costs as primary drivers. Due to its technology and platform effect, Mohawk’s corporate overhead is expected to increase at a slower pace than sales. Its fixed operating costs long-term target goal is 5%, which follows the current trend (2019 – 19%, 2020 – 13%). It aims for an adjusted EBITDA of 13-15%.

Management Team

Yaniv Sarig has been Mohawk’s President and Chief Executive Officer since September 2018. He is also a co-founder of Mohawk Group Inc. Mr. Sarig has served as the President and Chief Executive Officer of Mohawk Group Inc. since June 2014. Before his role at Mohawk, he led the Financial Services Engineering department at Coverity, a software startup providing code and security solutions to top financial institutions and hedge funds in New York to include the New York Stock Exchange, Nasdaq, JPMorgan Chase and Barclays. Before his Coverity role, Mr. Sarig held lead technical roles at Bloomberg and EPIQ Systems Inc. (NASDAQ: EPIQ). He holds a Bachelor of Science from Touro College. He is fluent in English, French, Hebrew and C++.

Fabrice Hamaide has been the Chief Financial Officer of Mohawk since September 2018. He has also retained the position of Chief Financial Officer for Mohawk Group Inc. since July 2017. Before Mohawk, Mr. Hamaide held numerous financial, CFO and presidential roles in various technological and consumer product companies across Europe and the United States, including Piksel Inc., Atari, Parrot and Logitech. Mr. Hamaide holds an impressive set of credentials, including an MBA from Columbia Business School, an MS in Information Systems Design from Sorbonne University, and a BS in Applied Mathematics from Jussieu University.

Mihal Chaouat-Fix has been the Chief Product Officer for Mohawk since September 2018. Prior to taking this role within the company, she was the Chief Operating Officer, handling the day-to-day leadership and operational management of Mohawk. Before joining Mohawk, Ms. Chaouat-Fix worked in various roles at Gottex Models Ltd. At this international fashion swimwear firm, her focus on marketing, operations and manufacturing saw supply chain and distribution of 12 million units per year to over 40 countries worldwide.

Tomer Pascal has been the Chief Revenue Officer for Mohawk since 2018. He has also served as the Chief Revenue Officer for Mohawk Group Inc. since 2017. Before he joined the Mohawk team, he was the Chief Executive Officer and co-founder of OMG Studios. Throughout his career, Mr. Pascal has held many different co-founder and general management roles, focusing on companies’ marketing and revenue growth in the media and technology industries.

Roi Zahut has held the role of Chief Technology Officer for Mohawk since 2019. Before Mohawk, he served in numerous roles, including CTO of the Advanced Analytics global consulting team at IBM and architect of IBM Metropulse. While in Israel, Mr. Zahut held several senior technical, business and data science roles in startups and consulting to include IBM Israel, Brainbow Ltd. and Matrix IT Ltd. He holds an MSc in Neuroscience with distinction from Bar Ilan University.

Mohawk Group Holdings Inc. (MWK), closed Wednesday's trading session at $29.50, up 5.3571%, on 915,173 volume with 9,396 trades. The average volume for the last 3 months is 1,068,893 and the stock's 52-week low/high is $1.60000002/$48.9900016.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element, Inc. (NASDAQ:NETE) (“Net Element” or the “Company”), today reports its financial results for the calendar year ended December 31, 2020, and updates shareholders on the pending merger with privately-held Mullen Technologies, Inc. (“Mullen”), a Southern California-based electric vehicle (“EV”) company, in a stock-for-stock reverse merger in which, subject to consummation, Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger Company.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Wednesday's trading session at $10.92, up 1.8657%, on 591,938 volume with 3,272 trades. The average volume for the last 3 months is 740,730 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) was featured today in a publication from MiningNewsWire, examining how the federal government of the United States is working toward helping battery manufacturers and miners in America expand into the neighboring country, Canada. This is part of the government’s strategy to counter Chinese dominance in the market and improve the regional production of minerals that are used to make electric cars.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Wednesday's trading session at $5.68, up 5.5762%, on 4,493,912 volume with 21,030 trades. The average volume for the last 3 months is 000,000 and the stock's 52-week low/high is $1.04999995/$7.82999992.

Recent News

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF)

The QualityStocks Daily Newsletter would like to spotlight Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF).

Nextech (OTCQB: NEXCF) (NEO: NTAR.NE) (CSE: NTAR) (FSE: N29), a leading provider of virtual and augmented reality (“AR”) experience technologies and services for eCommerce, education, advertising, conferences and events, has inked a three-year deal with The Broad Institute of MIT and Harvard. Under the agreement, Nextech will host over a dozen seminars through its Virtual Experience Platform. To view the full article, visit https://ibn.fm/ugNZg

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF), based in Vancouver, Canada, is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, with technology ranging from simple 3D images to using 360-degree videos. Nextech AR provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales.

The company is currently pursuing four unique verticals with its innovative technology, including:

  • Virtual Conference Platform: Nextech’s advanced Augmented Reality and Video Learning Experience Platform for Events leverages an SaaS model to give organizations the ability to create engaging virtual event management and learning experiences. Automated closed captions and translations for over 64 languages are available. The global virtual events market was valued at $90 billion in 2020 by Grandview Research, and it’s expected to reach more than $400 billion by 2027.
  • ARitize™ for eCommerce: Launched in early 2019, the company’s SaaS platform for webAR in eCommerce serves as a ‘full funnel’ end-to-end e-commerce solution for the AR industry. The solution includes the Aritize360 app for 3D product capture, ‘Try it On’ technology for online apparel, 3D and 360-degree product views, ‘one click buy’ and much more.
  • ARitize™ 3D/AR Advertising Platform: Launched in Q1 2020, this ad platform is being marketed as the industry’s first end-to-end solution leveraging 3D asset creation for 3D/AR ads. In 2019, according to IDC, global advertising spend totaled roughly $725 billion.
  • ARitize™ Hollywood Studios: The studio is in development as a means of producing immersive content using 360-degree videos and augmented reality as primary display platforms.

Unique Marketing Strategy

Nextech AR’s efforts to disrupt the market for web-based augmented reality for e-commerce are supported by a unique go to market strategy. First, the company seeks to build or acquire platforms targeting a number of rapid growth industries, most notably AR, edTech, e-commerce, 3D/AR advertising and virtual & hybrid events.

After identifying these market opportunities, the company seeks to integrate new AR technologies into existing or novel platforms in an effort to secure market share and promote growth. These technologies include WebAR, Human Holograms, 360 Portals, ScreenAR, Genie in the bottle and AiRShow.

Nextech AR then aims to leverage these platforms to land and expand partnerships with a number of blue chip customers. The company’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University.

Growth Capital

Nextech AR generates revenue through a software-as-a-service model from technology services, delivery of service revenue and sales of products through e-commerce.

As noted in its latest investor presentation, the company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase. The company also realized greater than 235% revenue growth for calendar 2020, reporting $20 million for the 12-month period. Nextech AR attributes its 2020 increase in revenues to the contracts secured with new customers, expanded agreements with existing customers and additional conversions from e-commerce channels.

With its newly launched 3D ad network now bolstering its operations, Nextech AR is projecting revenues in excess of $50 million for 2021.

Recent Company Highlights

  • February 16, 2021: The company announced it has hired Zak Mcleod, formerly of Fastly, as its new Senior Director of Sales – EMEA. The company also announced that Rory Ganness, formerly of Salesforce.com, has joined the Nextech team as Director of Enterprise Sales – North America.
  • February 11, 2021: The company announced the launch of version 2.0 of its AiR Show app, an application that turns top music artists into interactive ‘live’ holograms, providing an immersive and engaging AR experience.
  • February 8, 2021: The company announced the launch of new standardized chat features within its Virtual Experience Platform (VXP) and recently-launched ARoom collaborative streaming solution. Nextech will also offer the chat platform as a stand-alone SaaS service externally, increasing the company’s revenue potential for 2021.
  • January 26, 2021: The company announced, in partnership with ARB Meetings and Events, it has signed a six-figure annual contract to supply its InfernoAR video conferencing and virtual events platform to NAMD.
  • January 25, 2021: The company announced that Strategic Site Selection (SSS), a 15 year old site selection leader in the meeting and events industry, has selected Nextech AR as a preferred channel partner, making Nextech’s industry leading virtual experience platform and services available to SSS clients.
  • January 20, 2021: The company announced that Microsoft’s Azure Cloud Services platform will be a standard offering across its virtual experience platforms and consumer apps, enabling hyper-scalable, secure and immersive events and applications for users.
  • January 15, 2021: The company signed a renewal agreement with Poly with an initial value of $470,000 for a six-month term and the potential for additional revenue after the six months.

Management Team

Evan Gappelberg is CEO and Founder of Nextech AR. He is an experienced operating executive specializing in creating, funding and running hyper-growth startups in both the public and private sectors. Notably, he took Take-Two Interactive Software Inc. (NASDAQ: TTWO) public with a market cap of $30 million and played a key role in guiding its growth to a current market cap of roughly $14 billion. Mr. Gappelberg has extensive experience as both a hands-on operating executive and a public markets professional.

Paul Duffy is the company’s President. He is a serial entrepreneur with over 25 years of experience in successfully starting, expanding, diversifying and selling global technology companies. Mr. Duffy is the creator of the HumaGram and inventor of the patent for Holographic Telepresence over the Internet (TOIP).

Augen Winschel is the COO of Nextech AR. He is an 18-year SAP executive with over 20 years of leadership experience in the areas of business management, business operations, marketing, product management, digital business and enterprise artificial intelligence.

Kashif Malik, CPA, CA, is the company’s CFO. He has over 15 years of financial experience spanning IPOs, M&A activity, corporate restructuring and capital raising. Mr. Malik has worked globally with public and private companies, including Merck & Company Inc. (NYSE: MRK), Real Matters Inc. (TSX: REAL) and Constellation Software Inc. (TSX: CSU). He obtained his Chartered Accountant designation while working at Deloitte.

Hareesh Acchi is the company’s President of 3D/AR Advertising. He is a 20-year Microsoft technology veteran with experience leading digital transformation and scaling businesses and enterprise organizations across the advertising industry.

Nextech AR Solutions Corp. (NEXCF), closed Wednesday's trading session at $3.46, up 1.4663%, on 170660 volume with 00 trades. The average volume for the last 3 months is 5,421,898 and the stock's 52-week low/high is $3.18799996/$5.41120004.

Recent News

Healthtech Solutions Inc. (OTC: HLTT)

The QualityStocks Daily Newsletter would like to spotlight Healthtech Solutions Inc. (OTC: HLTT).

Healthtech Solutions, Inc. (OTC: HLTT) (“HLTT” or the “Company”)  today announces that it has entered into an agreement to acquire a wholly-owned subsidiary, Healthtech Oncology, Inc., which will own a 100% interest in Varian Biopharmaceuticals Inc. (“Varian Bio”), a precision oncology company developing novel therapeutics for the treatment of cancer. Varian Bio is developing a proprietary atypical protein kinase C iota (“aPKCi”) inhibitor for the treatment of various tumor types. Varian Bio’s lead drug candidate, VAR-101, is being developed in a topical formulation for the treatment of basal cell carcinoma.  

Healthtech Solutions Inc. (OTC: HLTT), through its Mediscan Inc. subsidiary, created a cloud-based software for ultrasound technology that reconstructs the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format.

The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems.

Healthtech Solutions Inc. acquired all of Mediscan’s capital stock in a reverse acquisition transaction on November 13, 2020. On November 23, 2020, the shareholders of Healthtech Solutions Inc. consented to a resolution changing its name to Healthtech Solutions Inc.

The company’s operational focus for the immediate future will be on Mediscan’s continuing research and development of imaging, development of other medical solutions, and making strategic investments.

Mediscan Technology

Mediscan software transforms an ultrasound analog 2D grayscale image into a digital 3D HD format. When paired with a portable ultrasound machine, the software application can enable these detailed and quantifiable scans by on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (EMS) personnel, and technicians in isolation wards and emergency rooms.

Once an image has been captured in 2D, it is converted using a cloud-based software application process – a process that takes approximately one minute. The completed 3D image is viewed on the medical professional’s computer monitor, pad or smartphone at the point of service. This technique can generate 3D medical images of different organs, such as the heart, lungs, tendons, skin and nerves.

This cloud-based software application for ultrasound devices is easy to use anywhere there is an internet connection. The application provides the convenience of point of care ultrasound with the image quality of CT or X-ray and the safety of very expensive MRI technology. For patients, it provides a convenient and comfortable medical experience.

Mediscan has filed two patent applications with the United States Patent and Trademark Office, both for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS).

The technology will initially be available as medical software-as-a-service (SaaS), resulting in cost-efficiency. The SaaS model eliminates the customer’s need for external hardware and software solutions, as well as technical maintenance. The SaaS model is already widely used in the health care industry, most notably for clinical information systems and supply chain management, revenue cycle management and billing. Benefits include increased patient and physician satisfaction, lower operational costs, better workflows and more. Per company data, the Mediscan system is fast and efficient, which could generate a significant cost reduction.

Health and Wellness Applications

Mediscan’s technology has shown success in musculoskeletal (MSK), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung and or the MSK sub-system, the application directly images the target area, saves it as a reference, and then compares it to previous images, helping to determine if the patient is progressing or regressing.

The cardiac application combines imaging with a therapy system that detects and classifies cardiac myopathy conditions via an “entrainment” process similar to that used in treating tachycardia. This application also features a comparison function where the latest imagery is interpreted against previous vetted cardiac images to detect progression or regression.

Mediscan’s technology can also be utilized on the wellness market for diagnostics and support in a wide range of situations, such as sports injuries, physical therapy and dermatological indications.

COVID-19 Applications

COVID-19 causes complications with patients’ cardiovascular and pulmonary systems. Mediscan’s technology could help meet the growing need for advanced diagnostic and monitoring imaging at the point of care.

Portable ultrasounds equipped with Mediscan’s application are a flexible and easy-to-use solution for health care providers to evaluate, triage and diagnose COVID-19 effects on contagious patients in isolation where MRI, CT or PET Scans are not accessible. With this technology, health care providers can easily detect lung lesions or heart muscle shredding, which often appear in patients with COVID-19.

Diagnostic Imaging Market Outlook

With the increasing demand for early diagnosis and a widening scope of clinical applications, any promising technological advancements in the field constitute a significant investment opportunity. The global market is also being driven by technological advances in the diagnostic imaging industry.

As standard ultrasound 2D greyscale images are generally the norm, and 3D imaging typically requires the use of CT, PET, MRI or X-ray technology, Mediscan’s application could have a dramatic impact on the medical imaging industry, meeting the need for imaging equipment and devices that can generate human anatomy data in 3D.

The global market for diagnostic imaging was estimated at approximately $100 billion in 2016 (https://ibn.fm/xtInK) and was expected to grow steadily, creating a promising opportunity for Mediscan to distribute its technology and achieve its mission as a developer and distributor of medical imaging solutions designed for both long-term care and acute and emergency medical services.

Management Team

David Rubin is the Chairman and CEO of Healthtech Solutions Inc. Mr. Rubin has been in the financial services business for over 20 years. Concurrently, he is also the CEO of Capital Stack LLC and CEO of eProdigy Financial LLC. Rubin attended Kingsborough Community College from 1985 to 1988.

Manuel Iglesias is the President and a Director of Healthtech Solutions Inc. Mr. Iglesias has practiced law since 1980, specializing in business law, merger and acquisitions, securities and health care. Mr. Iglesias served as President, CEO and a board member of Hygea Holdings Corp., which provided primary care medical services throughout Florida and Georgia. He served as the National Chairman of the Republican National Lawyers Association in 2019 and 2020. Mr. Igleisias was awarded his MBA degree from the University of Chicago in 1981, a Juris Doctorate from the University of Chicago in 1979, and a BS in Foreign Service from Georgetown University in 1976.

Denis Kleinfeld is a Director of Healthtech Solutions Inc. and General Counsel and a Director of Mediscan Inc. Mr. Kleinfeld has extensive experience in business planning and regulatory compliance. Mr. Kleinfeld is a renowned expert in international tax and estate planning law. Kleinfeld received his Juris Doctorate from the Loyola University of Chicago School of Law in 1970.

Richard F. Parker is the Chief Research Officer of Mediscan Inc. He developed the technology that is the foundation of Mediscan’s business plan. Before he joined Mediscan, Mr. Parker was employed as an engineer and business executive for 37 years. Previously, he was President and Chief Technology Officer of CytoWave LLC. Mr. Parker was awarded a patent for technology that supported a Method and Apparatus for Generating a Therapeutic Magnetic Waveform. During the past 10 years, Mr. Parker has published 14 papers and made numerous presentations focused on magnetic imaging and treatment of sports and equine injuries. He obtained his MSEE degree from the Georgia Institute of Technology in 1971.

Healthtech Solutions Inc. (HLTT), closed Wednesday's trading session at $3.19, up 51.1848%, on 26,291 volume with 80 trades. The average volume for the last 3 months is 33,778 and the stock's 52-week low/high is $0.024/$4.00.

Recent News

Ideanomics Inc. (NASDAQ: IDEX)

The QualityStocks Daily Newsletter would like to spotlight Ideanomics Inc. (NASDAQ: IDEX).

IDEX Biometrics ASA, today announced that Derek P. D’Antilio will step down from his position as Chief Financial Officer effective 23 April 2021. Mr. D’Antillio has accepted a position with another company. IDEX has initiated the process of finding his successor and expects to appoint the Company’s next CFO by 1 May 2021. The company has appointed Erling Svela, VP of Finance of IDEX as interim CFO effective 24 April 24 2021. Mr. D’Antilio will remain with IDEX in an advisory role to assist with an orderly transition. Also today, the company was announced its Full Year 2020 operating results for the period ended December 31, 2020 (a full copy of the Company's annual 10-K report is available at www.sec.gov ).

Ideanomics Inc. (NASDAQ: IDEX) is a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products. Ideanomics is currently divided into two divisions – mobility and capital. These divisions provide shareholders with access to disruptive and high-growth opportunities.

The company expects 2021 to be another growth year after it raised approximately $400 million over the past six months. This funding has already been put to good use with acquisitions of Wireless Advanced Vehicle Electrification (WAVE) and Timios. With roughly $200 million still on the balance sheet, Ideanomics continues to look for new investments and acquisitions in revenue-based opportunities focused on EV and fintech businesses.

Founded in 2004, Ideanomics is headquartered in New York, New York, with additional offices in Hangzhou, Beijing and Qingdao, China. Its current operations span the United States, China, Ukraine and Malaysia.

Ideanomics Mobility

Ideanomics Mobility is focused on the EV market. The global commercial EV market was valued at $34.7 billion in 2018 and is expected to grow at a CAGR of 39.9% through 2022 to reach a total of $132.73 billion (https://ibn.fm/pPrf4). According to a survey by Grand View Research, the global EV charging infrastructure market is also expected to grow and reach $144.97 billion in 2028, expanding at a CAGR of 33.4% from 2021 to 2028.

This growth is expected to be driven by increased support of electric vehicles from the public, as well as the current U.S. administration, which has a goal of achieving a 100% clean-energy economy.

The Ideanomics Mobility unit consists of five companies:

  • Mobile Energy Global (MEG) – Wholly owned China-based service provider of the Sales-to-Finance-to-Charging (S2F2C) business model to assist commercial fleet operators on EV enablement. Recent sales include 2,000 units of D1, BYD’s custom electric ride-hailing vehicle.
  • Medici Motor Works – Wholly owned North America division. MMW will develop zero-emissions specialty vehicles, trucks, buses and vans for the North American market.
  • Wireless Advanced Vehicle Electrification (WAVE) – Wholly owned Utah-based commercial EV charging technology company with a specialized offering of in-ground wireless charging for commercial vehicles. WAVE’s chargers power the Antelope Valley Transportation Authority, the largest municipal EV bus system in the country. Its revenue for 2020 exceeded $7 million, and it boasts a robust pipeline for 2021 and beyond.
  • Treeletrik – Majority investment in Malaysian-based OEM will service a high-demand market – electric delivery mopeds. Treeletrik has obtained certifications in Thailand and Indonesia, with orders secured for 2021. Its North American marketing program is expected to commence in 2021. As a part of the ESG initiative, one tree will be planted for every unit sold.
  • Solectrac – Minority investment in California-based electric tractor company. Solectrac manufactures 100% electric tractors to benefit farmers, crops and the planet at a time when the agriculture market remains virtually unaddressed by EV solutions.
  • Silk EV – Minority investment in hyper car and performance car design company, which provides access to the high-end battery and charging technology development ecosystem.

Ideanomics is generating EV revenue from its Sales to Financing to Charging (S2F2C) business model, which features three operating areas:

  1. Vehicle and Battery Sales: Medici, Treeletrik and Solectrac cover three key market segments
  2. Financing, Leasing and Insurance: Offering financial services to fleet customers, commission delivery and origination fee-based revenue
  3. Charging and Energy Services: Offering charging as a service, battery swap programs and WAVE wireless charging products

Ideanomics Capital

Ideanomics Capital is focused on providing disruptive fintech solutions across the entire board of financial services, ranging from financial markets to digital securities and assets to mortgages and more. More mainstream institutions and a growing number of companies have increased their digital securities services, along with institutional investments boosting bitcoin and the emergence of favorable regulatory developments, creating ample opportunities for widespread adoption of financial technologies.

Additionally, the U.S. real estate industry is ripe for technologization, as it currently is fragmented, antiquated, opaque and largely untouched by tech innovation. However, the expanding market, with U.S. home sales expected to grow 21.9% in 2021, and the increased digitization of all business spaces are expected to promote a digital-first experience as the new industry standard this year and beyond (https://ibn.fm/DwsUv).

The Ideanomics Capital unit consists of five companies:

  • Timios – Wholly owned subsidiary bringing real estate into the 21st century by providing value-add, fee-based services addressing the title and closing process of home buying and mortgage transactions. Timios works to create transparency and efficiency within the market. Timios ended 2020 as a cash flow and EBITDA positive business.
  • The Delaware Board of Trade (DBOT) – Wholly owned FINRA-regulated ATS and broker dealer based in Delaware.
  • Liquefy – Minority investment bringing innovation to investment in real assets with blockchain technology by increasing efficiency in fractional ownership, lowering entry to investment barriers and unlocking liquidity in assets that were previously illiquid.
  • Technology Metals Market (TM2) – Minority investment in UK company delivering a direct investment and trading market for technology metals with a newly accessible technology metals asset class for inventory diversification. The traded metals are 100% backed by physical metals.
  • Intelligenta – Investment providing AI and machine learning solutions for financial institutions and regulators.

Management Team

Alf Poor is Ideanomics’ Chief Executive Officer. He is a client-focused and profit-driven executive who has a track record of success in rapidly growing technology companies and large, multi-national organizations. Mr. Poor’s expertise includes business planning, financing and creating and implementing corporate governance policies, as well as handling management across organizations. His specialization is working with cross-border and multi-national startups. Before taking the CEO role at Ideanomics, he was the CEO for Global Data Sentinel.

Conor McCarthy is the company’s Chief Financial Officer. He is a strategic and operationally oriented management-level professional. His extensive international experience is within the fintech, data science and advertising technology sectors. Mr. McCarthy has experience with public companies, PE, and VC-backed firms. His specializations are financial and management reporting, planning and analysis, financial modelling, performance metrics, KPIs, venture borrowing, Series A equity funding, ERP system implementation, international business operations, and acquisition due diligence and integration. Before joining Ideanomics, Mr. McCarthy most recently held a CFO position at OS33. Prior to that, he was CFO for Intent Media Inc.

Kate Lam is the company’s Managing Director of Financial Products. She is highly regarded for her fixed income capital marketing skills across Asia and the United States. Ms. Lam has over 25 years of experience in the financial markets industry, dealing with many asset classes and clients. Having spent a few years in the fintech startup industry, her skills bridge the gap between traditional financial assets and new technological innovations. She has held senior management positions at Bear Sterns, Deutsche Bank and Standard Chartered Bank.

Keith Byers is Ideanomics’ Senior Vice President of Operations. He has extensive experience managing strategic relationships with key clients and deepening the relationships through innovation and successful engagement strategies. Before Ideanomics, Mr. Byers was the Managing Partner and Head of Operations for Gain Theory. He has a Master of Arts – MA, Economics from Heriot-Watt University and a Master of Science – Economics from The University of Edinburgh.

Tony Sklar is the company’s Senior Vice President of Investor Relations. He is a communication strategist and has worked for multi-faceted companies with global operations. Mr. Sklar handles omni-channel distribution using intelligence platforms and data insights for strategic planning, international expansion and marketing channels. His specialties include project management with digital strategy and transformation, ICO, marketing, blockchain and strategic partnerships. In addition to his role with Ideanomics, he is also a board member for the Delaware Board of Trade and the host and senior technology reporter for Far From TV.

Ideanomics Inc. (IDEX), closed Wednesday's trading session at $2.92, up 1.3889%, on 23,092,369 volume with 58,590 trades. The average volume for the last 3 months is 43,926,636 and the stock's 52-week low/high is $0.370000004/$5.5300002.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) was featured today in a publication from BioMedWire, examining how, as the coronavirus vaccines become more accessible in the United States, two infectious disease experts from Georgetown University Medical Center assert that protecting oneself against the presymptomatic and asymptomatic spread of the SARS-CoV-2 virus, which causes the coronavirus, is the key to ending the pandemic.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $2.39, up 3.0172%, on 171,552 volume with 873 trades. The average volume for the last 3 months is 1,760,046 and the stock's 52-week low/high is $1.59000003/$5.61999988.

Recent News

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific Inc. (OTCQB: BRSF) (the “Company”), a neurology focused medical device and software company, has announced it has received its first purchase order for its NeuroCap ™, a pre-gelled, disposable EEG headset, from the Department of Veterans Affairs – VA Medical Centers for one of its hospitals. “Our team at Brain Scientific is proud to start what it hopes will be a long-term relationship to serve patient needs at VA Medical Centers and do our part to help reduce risk factors for both patients and staff. Our disposable EEG NeuroCap diminishes the potential for cross contamination, HAI and exposure for staff members and patients. Sanitation is a major concern for hospitals and is even more crucial in COVID-19 times as neurodiagnostic teams are urged to find alternatives to reusable products,” said Amy Griffith, VP Strategy and Business Development of Brain Scientific, Inc.

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

  • NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

  • NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

  • NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
  • NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

  • Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
  • An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Wednesday's trading session at $1.45, up 11.5385%, on 7,598 volume with 18 trades. The average volume for the last 3 months is 8,226 and the stock's 52-week low/high is $0.100000001/$3.00999999.

Recent News

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)

The QualityStocks Daily Newsletter would like to spotlight Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF).

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF) was featured today in a publication from Green Car Stocks, examining how, despite its relative youth, the electric vehicle (“EV”) industry has made a lot of progress, especially in Europe. Several European countries have pledged to phase out internal combustion engine (“ICE”) vehicles in exchange for zero-emission electric vehicles over the next few decades, with Norway leading in terms of EV market share (54%). According to automotive industry analyst Schmidt Automotive Research, 2021 may be a good year for battery electric vehicles (“BEV”), with EV sales in Western Europe, which includes Britain, Germany, Norway, Italy, Spain, and France, projected to surpass more than a million units.

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.

Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).

Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.

PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration

In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.

Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.

Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.

PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.

Hydrogen Industry Outlook

The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.

Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.

“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).

A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.

The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.

With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.

“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.

Management Team

Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.

Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.

Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.

Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.

Clean Power Capital Corp. (OTC: MOTNF), closed Wednesday's trading session at $1.42, up 4.5271%, on 302,509 volume with 153 trades. The average volume for the last 3 months is 171,613 and the stock's 52-week low/high is $0.03325/$2.78999996.

Recent News

AzurRx BioPharma Inc. (NASDAQ: AZRX)

The QualityStocks Daily Newsletter would like to spotlight AzurRx BioPharma Inc. (NASDAQ: AZRX).

AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today provided key takeaways from its conference call reporting on the topline results from its Phase 2b OPTION 2 clinical trial investigating MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). The conference call, held on March 31, 2021, at 4:30 p.m. ET, featured James Sapirstein, President, CEO and Chairman of AzurRx, and Dr. James Pennington, Chief Medical Officer, discussing the recently completed OPTION 2 study, and the company’s plans to develop an optimized formulation of MS1819 for ongoing clinical investigation.

AzurRx BioPharma Inc. (AZRX) is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins.

The company’s lead drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients suffering from cystic fibrosis and chronic pancreatitis.

AzurRx has already completed two Phase 2 clinical trials for MS1819 and is currently pursuing approval through parallel monotherapy and combination therapy pathways.

The company was founded in 2014 and is headquartered in New York City, with scientific operations in Langlade, France, and clinical operations in Hayward, California.

MS1819 Clinical Trials

The two current ongoing clinical trials for MS1819 in cystic fibrosis (CF) are the Phase 2b Option 2 monotherapy trial and the Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (PERT), the current standard of care. Pending the Phase 2b trial outcome, the company intends to initiate a Phase 3 trial in cystic fibrosis.

  • Phase 2b CF Option 2 Trial – The study was initiated in Q3 2020, using MS1819 doses in enteric capsule form (2240mg and 4480mg). Topline data for the trial is anticipated in Q1 2021.
  • Phase 2 CF Combination Trial – The study was initiated in Q4 2019, using daily dose levels of PERT in combination with MS1819 dosages (700mg, 1120mg and 2240mg). Topline data is anticipated in Q2 2021.

These trials are currently addressing the treatment of EPI in patients with cystic fibrosis and chronic pancreatitis – an established global market with an estimated value in excess of $2 billion that has been growing at a CAGR greater than 20% over the past five years.

Results from AzurRx’s Phase 2b Option 2 trial of MS1819 in cystic fibrosis patients demonstrate that the non-porcine MS1819 lipase is well-tolerated by patients, with no significant safety signals observed at the 2240mg daily dose level.

“[W]e have evaluated four different enteric capsules and identified the best suitable formulation for MS1819 that provides gastroprotection of enzyme content and delayed release into the duodenum,” James Sapirstein, President & CEO of AzurRx, stated in a September 2020 news release (https://ibn.fm/27t4W). “Our clinical program continues to advance, and we are determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients.”

Financial Highlights

As of July 2020, AzurRx had raised gross cash capital of $22.1 million, including $15.2 million from Series B convertible preferred stock and warrants in July 2020 and $6.9 million from convertible promissory notes and warrants in December 2019 and January 2020. Notably, AzurRx solidified its financial position and created an effectively debt-free balance sheet by exchanging substantially all of its outstanding convertible notes into the Series B convertible preferred stock financing.

The company secured an additional $2.5 million in French Research Tax Credits, received in 2020, for the years 2017-2019 (https://ibn.fm/Qxk7O).

In a letter to shareholder, Sapirstein noted that ensuring the company maintains sufficient capital to support its business operations has been a key focus. He further stated that the company is in “a financially secure position” to complete its two Phase 2 MS1819 clinical trial programs and to begin preparations in 2021 for a pivotal Phase 3 study.

The company has no current plans to access additional financing, as it believes it has enough cash to fund existing operational and clinical objectives through Q3 2021.

Management Team

James Sapirstein is the President and CEO of AzurRx BioPharma. He was previously the CEO and a board member for ContraVir Pharmaceuticals Inc., which is now known as Hepion Pharmaceuticals Inc. (NASDAQ: HEPA). Mr. Sapirstein has almost 36 years of experience in the pharmaceutical industry, with expertise in drug development and commercialization. He currently serves on the Emerging Companies and Health Section boards of the BIO (Biotechnology Innovation Organization) and is Chairman Emeritus of BioNJ. He earned his Bachelor’s degree in Pharmacy from Rutgers University and has an MBA in management from Fairleigh Dickinson University.

Daniel Schneiderman is the Chief Financial Officer of AzurRx. He previously served as the CFO of Biophytis SA and its U.S. subsidiary, Biophytis, Inc., clinical-stage biotechnology companies focused on the development of pharmaceutical candidates for age-related diseases. He was appointed to the AzurRx position in January 2020, bringing to the team over 18 years of experience in capital markets and finance operations. Mr. Schneiderman holds a degree in economics from Tulane University.

James Pennington, M.D., is the Chief Medical Officer of AzurRx. Before joining the team, he was the Chief Medical Officer and Senior Clinical Fellow for 11 years at Anthera Pharmaceuticals. Before becoming a part of the biotech industry, Dr. Pennington was on the Medical Faculty of Harvard Medical School for 10 years. He received his medical degree from Oregon Health & Science University.

Martin Krusin is the Senior Vice President for Corporate Development at AzurRx. He has 20 years of experience in business development, strategic marketing, financing and operations in the health care, financial services and consulting sectors. Before joining AzurRx, he was the VP for Business Development at FluoroPharma Medical Inc. Mr. Krusin received his MBA from Columbia Business School in finance and marketing, an MPhil. in political economy from Oxford University and a BA in international relations from Swarthmore College.

Dinesh Srinivasan, Ph.D., is the Vice President for Translational Research at AzurRx. He has over 15 years of experience leading drug discovery and development in the pharmaceutical industry. He began his career as a post-doctorate fellow at Roche Palo Alto. Dr. Srinivasan received his MSc in Biotechnology from the University of Mumbai, India, and a Ph.D. in Pharmacology and Toxicology from the University of Arizona – Tucson.

Ted Stover is the Product Development Director at AzurRx. He joined the company in 2020 to oversee CMC and Project Management. Before joining AzurRx, he spent 20 years focused on manufacturing operations and analytical method development for all stages of pharmaceutical drug development. Mr. Stover earned his MBA from the University of Florida.

AzurRx BioPharma Inc. (AZRX), closed Wednesday's trading session at $1.34, up 3.0769%, on 17749496 volume with 32,840 trades. The average volume for the last 3 months is 9,503,228 and the stock's 52-week low/high is $0.510200023/$2.63000011.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CLXPF)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (OTC: CLXPF).

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) was featured today in a publication from FinancialNewsMedia.com, examining how psychedelic healing may sound like a fad from the Woodstock era, but it’s a field of study that’s gaining traction in the medical community as an effective treatment option for a growing number of mental health conditions. While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial. 

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Wednesday's trading session at $1.0431, up 8.374%, on 324,219 volume with 330 trades. The average volume for the last 3 months is 483,706 and the stock's 52-week low/high is $0.0284/$2.23499989.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Monday's trading